{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:34:12Z","timestamp":1788564852870,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012760","name":"Public Welfare Foundation","doi-asserted-by":"publisher","award":["BCF-XD-JC-20221205-17"],"award-info":[{"award-number":["BCF-XD-JC-20221205-17"]}],"id":[{"id":"10.13039\/100012760","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The combination of immune checkpoint inhibitors (ICIs) and chemotherapy has become the standard first-line treatment for advanced gastric cancer and gastroesophageal junction cancer (GC\/GEJC), yet reliable biomarkers predicting efficacy remain limited. We performed longitudinal plasma proteomic profiling in 31 patients receiving immunochemotherapy in this prospective observational cohort study. Serial plasma samples collected at baseline and every two treatment cycles were analyzed to identify dynamic protein changes correlated with therapeutic response and survival. The results showed that responders exhibited significantly lower baseline interleukin-15 (IL-15) levels (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.01). After two cycles of treatment, a 161.9% reduction in plasma Mucin-16 (MUC-16), also known as Cancer Antigen-125 (CA-125), was identified as an independent factor for prolonged overall survival (HR 7.40, 95%CI 2.22\u201324.60,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.001), which was validated by conventional serum CA-125 testing. Integrating baseline IL-15 with dynamic changes in MUC-16 and Matrix Metalloproteinase 12 (MMP12), the constructed composite risk model achieved an Area Under the Curve (AUC) of 0.799 for predicting response, and this model was also an independent factor for progression-free survival (HR 3.35, 95% 1.56\u20137.20,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.002). In summary, baseline IL-15 helps identify patients likely to benefit from immunochemotherapy, while MUC-16 and the integrated model facilitate dynamic monitoring of therapeutic efficacy. These findings provide new insights into non-invasive blood-based patient stratification and treatment optimization.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial registration<\/jats:bold>\n                    ChiCTR2300078000. Registered 27 November 2023\u2014prospectively registered,\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.chictr.org.cn\/hvshowproject.html?id=241839&amp;v=1.0\" ext-link-type=\"uri\">https:\/\/www.chictr.org.cn\/hvshowproject.html?id=241839&amp;v=1.0<\/jats:ext-link>\n                  <\/jats:p>","DOI":"10.1186\/s43556-026-00510-8","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:15:40Z","timestamp":1783397740000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Plasma proteomics-based liquid biopsy for predicting efficacy of PD-1-based immunochemotherapy in advanced gastric cancer: a prospective cohort study"],"prefix":"10.1186","volume":"7","author":[{"given":"Enqing","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0611-7495","authenticated-orcid":false,"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"issue":"3","key":"510_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"510_CR2","doi-asserted-by":"publisher","DOI":"10.1177\/10732748221099227","volume":"29","author":"Y Li","year":"2022","unstructured":"Li Y, Feng A, Zheng S, Chen C, Lyu J. Recent estimates and predictions of 5-year survival in patients with gastric cancer: a model-based period analysis. Cancer Control. 2022;29:10732748221099227. https:\/\/doi.org\/10.1177\/10732748221099227.","journal-title":"Cancer Control"},{"issue":"10294","key":"510_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2.","journal-title":"Lancet"},{"issue":"21","key":"510_CR4","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","volume":"330","author":"J Xu","year":"2023","unstructured":"Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. JAMA. 2023;330(21):2064\u201374. https:\/\/doi.org\/10.1001\/jama.2023.19918.","journal-title":"JAMA"},{"issue":"13","key":"510_CR5","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","volume":"25","author":"L Marcus","year":"2019","unstructured":"Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25(13):3753\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-4070.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"510_CR6","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","volume":"24","author":"ST Kim","year":"2018","unstructured":"Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449\u201358. https:\/\/doi.org\/10.1038\/s41591-018-0101-z.","journal-title":"Nat Med"},{"issue":"10","key":"510_CR7","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353\u201365. https:\/\/doi.org\/10.1016\/S1470-2045(20)30445-9.","journal-title":"Lancet Oncol"},{"issue":"1","key":"510_CR8","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12943-020-01274-7","volume":"19","author":"Y Jin","year":"2020","unstructured":"Jin Y, Chen DL, Wang F, Yang CP, Chen XX, You JQ, et al. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Mol Cancer. 2020;19(1):154. https:\/\/doi.org\/10.1186\/s12943-020-01274-7.","journal-title":"Mol Cancer"},{"issue":"10","key":"510_CR9","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41571-018-0074-3","volume":"15","author":"L Cabel","year":"2018","unstructured":"Cabel L, Proudhon C, Romano E, Girard N, Lantz O, Stern MH, et al. Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. Nat Rev Clin Oncol. 2018;15(10):639\u201350. https:\/\/doi.org\/10.1038\/s41571-018-0074-3.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"510_CR10","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1038\/s41416-022-01978-1","volume":"127","author":"E Zulato","year":"2022","unstructured":"Zulato E, Del Bianco P, Nardo G, Attili I, Pavan A, Boscolo Bragadin A, et al. Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors. Br J Cancer. 2022;127(11):2034\u201342. https:\/\/doi.org\/10.1038\/s41416-022-01978-1.","journal-title":"Br J Cancer"},{"key":"510_CR11","doi-asserted-by":"publisher","first-page":"8019","DOI":"10.2147\/IJN.S272378","volume":"15","author":"VC Kok","year":"2020","unstructured":"Kok VC, Yu CC. Cancer-Derived Exosomes: Their Role in Cancer Biology and Biomarker Development. Int J Nanomedicine. 2020;15:8019\u201336. https:\/\/doi.org\/10.2147\/IJN.S272378.","journal-title":"Int J Nanomedicine"},{"issue":"12","key":"510_CR12","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41571-020-0392-0","volume":"17","author":"A Dasari","year":"2020","unstructured":"Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB 3rd, Boland P, et al. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol. 2020;17(12):757\u201370. https:\/\/doi.org\/10.1038\/s41571-020-0392-0.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"510_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006616","volume":"12","author":"M Gao","year":"2024","unstructured":"Gao M, Wu X, Jiao X, Hu Y, Wang Y, Zhuo N, et al. Prognostic and predictive value of angiogenesis-associated serum proteins for immunotherapy in esophageal cancer. J Immunother Cancer. 2024;12(2):e006616. https:\/\/doi.org\/10.1136\/jitc-2022-006616.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"510_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s43556-025-00291-6","volume":"6","author":"Y Gao","year":"2025","unstructured":"Gao Y, Qi F, Zhou W, Jiang P, Hu M, Wang Y, et al. Liquid biopsy using plasma proteomics in predicting efficacy and tolerance of PD-1\/PD-L1 blockades in NSCLC: a prospective exploratory study. Mol Biomed. 2025;6(1):51. https:\/\/doi.org\/10.1186\/s43556-025-00291-6.","journal-title":"Mol Biomed"},{"issue":"3","key":"510_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031883","volume":"23","author":"O Sokolova","year":"2022","unstructured":"Sokolova O, Naumann M. Matrix metalloproteinases in Helicobacter pylori-associated gastritis and gastric cancer. Int J Mol Sci. 2022;23(3):1883. https:\/\/doi.org\/10.3390\/ijms23031883.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"510_CR16","doi-asserted-by":"publisher","first-page":"44193","DOI":"10.1038\/s41598-025-27936-4","volume":"15","author":"T Nakanishi","year":"2025","unstructured":"Nakanishi T, Imano M, Kohda M, Kato H, Kounami N, Yamada A, et al. Intraperitoneal immune microenvironment and efficacy of intraperitoneal chemotherapy in patients with gastric cancer and peritoneal metastasis. Sci Rep. 2025;15(1):44193. https:\/\/doi.org\/10.1038\/s41598-025-27936-4.","journal-title":"Sci Rep"},{"issue":"1","key":"510_CR17","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1038\/s41598-020-80351-9","volume":"11","author":"Z Cierna","year":"2021","unstructured":"Cierna Z, Smolkova B, Cholujova D, Gronesova P, Miklikova S, Cihova M, et al. Decreased levels of circulating cytokines VEGF, TNF-beta and IL-15 indicate PD-L1 overexpression in tumours of primary breast cancer patients. Sci Rep. 2021;11(1):1294. https:\/\/doi.org\/10.1038\/s41598-020-80351-9.","journal-title":"Sci Rep"},{"issue":"3","key":"510_CR18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00262-024-03631-7","volume":"73","author":"Q Tan","year":"2024","unstructured":"Tan Q, Gao R, Zhang X, Yang J, Xing P, Yang S, et al. Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients. Cancer Immunol Immunother. 2024;73(3):47. https:\/\/doi.org\/10.1007\/s00262-024-03631-7.","journal-title":"Cancer Immunol Immunother"},{"key":"510_CR19","doi-asserted-by":"publisher","first-page":"1349459","DOI":"10.3389\/fphar.2024.1349459","volume":"15","author":"J Sun","year":"2024","unstructured":"Sun J, Li X, Wang Q, Chen P, Zhao L, Gao Y. Proteomic profiling and biomarker discovery for predicting the response to PD-1 inhibitor immunotherapy in gastric cancer patients. Front Pharmacol. 2024;15:1349459. https:\/\/doi.org\/10.3389\/fphar.2024.1349459.","journal-title":"Front Pharmacol"},{"issue":"1","key":"510_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000599","volume":"8","author":"C Bergamaschi","year":"2020","unstructured":"Bergamaschi C, Pandit H, Nagy BA, Stellas D, Jensen SM, Bear J, et al. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-gamma, CXCL9 and CXCL10. J Immunother Cancer. 2020;8(1):e000599. https:\/\/doi.org\/10.1136\/jitc-2020-000599.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"510_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109438","volume":"36","author":"IH Seo","year":"2021","unstructured":"Seo IH, Eun HS, Kim JK, Lee H, Jeong S, Choi SJ, et al. IL-15 enhances CCR5-mediated migration of memory CD8(+) T cells by upregulating CCR5 expression in the absence of TCR stimulation. Cell Rep. 2021;36(4):109438. https:\/\/doi.org\/10.1016\/j.celrep.2021.109438.","journal-title":"Cell Rep"},{"issue":"2","key":"510_CR22","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/path.1198","volume":"198","author":"E Kerkela","year":"2002","unstructured":"Kerkela E, Ala-aho R, Klemi P, Grenman S, Shapiro SD, Kahari VM, et al. Metalloelastase (MMP-12) expression by tumour cells in squamous cell carcinoma of the vulva correlates with invasiveness, while that by macrophages predicts better outcome. J Pathol. 2002;198(2):258\u201369. https:\/\/doi.org\/10.1002\/path.1198.","journal-title":"J Pathol"},{"issue":"2","key":"510_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001428","volume":"8","author":"PF Fiore","year":"2020","unstructured":"Fiore PF, Di Matteo S, Tumino N, Mariotti FR, Pietra G, Ottonello S, et al. Interleukin-15 and cancer: some solved and many unsolved questions. J Immunother Cancer. 2020;8(2):e001428. https:\/\/doi.org\/10.1136\/jitc-2020-001428.","journal-title":"J Immunother Cancer"},{"issue":"19","key":"510_CR24","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1038\/sj.onc.1201775","volume":"16","author":"C Barzegar","year":"1998","unstructured":"Barzegar C, Meazza R, Pereno R, Pottin-Clemenceau C, Scudeletti M, Brouty-Boye D, et al. IL-15 is produced by a subset of human melanomas, and is involved in the regulation of markers of melanoma progression through juxtacrine loops. Oncogene. 1998;16(19):2503\u201312. https:\/\/doi.org\/10.1038\/sj.onc.1201775.","journal-title":"Oncogene"},{"issue":"13","key":"510_CR25","doi-asserted-by":"publisher","first-page":"4802","DOI":"10.1117\/12.869070","volume":"9","author":"H Kuniyasu","year":"2003","unstructured":"Kuniyasu H, Ohmori H, Sasaki T, Sasahira T, Yoshida K, Kitadai Y, et al. Production of interleukin 15 by human colon cancer cells is associated with induction of mucosal hyperplasia, angiogenesis, and metastasis. Clin Cancer Res. 2003;9(13):4802\u201310. https:\/\/doi.org\/10.1117\/12.869070.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"510_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03892-x","volume":"25","author":"R Zhang","year":"2025","unstructured":"Zhang R, Jiang Q, Guo R, Guo K, Qiu J. Unveiling the power of plumbagin: revitalizing exhausted T cells to combat tongue cancer. Cancer Cell Int. 2025;25(1):271. https:\/\/doi.org\/10.1186\/s12935-025-03892-x.","journal-title":"Cancer Cell Int"},{"key":"510_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1462221","volume":"15","author":"MJ Newman","year":"2024","unstructured":"Newman MJ. Invention and characterization of a systemically administered, attenuated and killed bacteria-based multiple immune receptor agonist for anti-tumor immunotherapy. Front Immunol. 2024;15:1462221. https:\/\/doi.org\/10.3389\/fimmu.2024.1462221.","journal-title":"Front Immunol"},{"issue":"48","key":"510_CR28","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1038\/s41388-022-02493-6","volume":"41","author":"I Lakshmanan","year":"2022","unstructured":"Lakshmanan I, Marimuthu S, Chaudhary S, Seshacharyulu P, Rachagani S, Muniyan S, et al. Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma. Oncogene. 2022;41(48):5147\u201359. https:\/\/doi.org\/10.1038\/s41388-022-02493-6.","journal-title":"Oncogene"},{"key":"510_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2019.120187","volume":"206","author":"B Szymanska","year":"2020","unstructured":"Szymanska B, Lukaszewski Z, Hermanowicz-Szamatowicz K, Gorodkiewicz E. A biosensor for determination of the circulating biomarker CA125\/MUC16 by Surface Plasmon Resonance Imaging. Talanta. 2020;206:120187. https:\/\/doi.org\/10.1016\/j.talanta.2019.120187.","journal-title":"Talanta"},{"issue":"1","key":"510_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37979-8","volume":"14","author":"Lung Cancer Cohort C","year":"2023","unstructured":"Lung Cancer Cohort C. The blood proteome of imminent lung cancer diagnosis. Nat Commun. 2023;14(1):3042. https:\/\/doi.org\/10.1038\/s41467-023-37979-8.","journal-title":"Nat Commun"},{"issue":"18","key":"510_CR31","doi-asserted-by":"publisher","first-page":"10279","DOI":"10.1111\/jcmm.15684","volume":"24","author":"S Wang","year":"2020","unstructured":"Wang S, You L, Dai M, Zhao Y. Mucins in pancreatic cancer: a well-established but promising family for diagnosis, prognosis and therapy. J Cell Mol Med. 2020;24(18):10279\u201389. https:\/\/doi.org\/10.1111\/jcmm.15684.","journal-title":"J Cell Mol Med"},{"issue":"4","key":"510_CR32","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3892\/ijo.2020.4989","volume":"56","author":"C Liu","year":"2020","unstructured":"Liu C, Deng S, Jin K, Gong Y, Cheng H, Fan Z, et al. Lewis antigen\u2011negative pancreatic cancer: an aggressive subgroup. Int J Oncol. 2020;56(4):900\u20138. https:\/\/doi.org\/10.3892\/ijo.2020.4989.","journal-title":"Int J Oncol"},{"issue":"8","key":"510_CR33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.13201","volume":"3","author":"L Zhang","year":"2020","unstructured":"Zhang L, Han X, Shi Y. Association of MUC16 mutation with response to immune checkpoint inhibitors in solid tumors. JAMA Netw Open. 2020;3(8):e2013201. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.13201.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"510_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004688","volume":"10","author":"M Hwang","year":"2022","unstructured":"Hwang M, Canzoniero JV, Rosner S, Zhang G, White JR, Belcaid Z, et al. Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy. J Immunother Cancer. 2022;10(6):e004688. https:\/\/doi.org\/10.1136\/jitc-2022-004688.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"510_CR35","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.3390\/cancers17122001","volume":"17","author":"F Kaczmarek","year":"2025","unstructured":"Kaczmarek F, Marcinkowska-Gapinska A, Bartkowiak-Wieczorek J, Nowak M, Kmiecik M, Brzezinska K, et al. Blood-Based Biomarkers as Predictive and Prognostic Factors in Immunotherapy-Treated Patients with Solid Tumors-Currents and Perspectives. Cancers (Basel). 2025;17(12):2001. https:\/\/doi.org\/10.3390\/cancers17122001.","journal-title":"Cancers (Basel)"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00510-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00510-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00510-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:15:41Z","timestamp":1783397741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00510-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["510"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00510-8","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University (approval number 2023-SR-353). Written informed consent was obtained from all participants. This study was registered with the China Clinical Trial Registry (ChiCTR2300078000).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The participants have provided formal written consent for the use of their data and any personal identifiers for the purpose of this publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M.W., M.G., X.Z., D.C., and C.Z., were employed by Jiangsu Simcere Diagnostics Co., Ltd. The other authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}